Time filter

Source Type

Atlanta, GA, United States

Markman M.,Cancer Treatment Centers of America
Oncology (Switzerland) | Year: 2013

Cytotoxic chemotherapy has been shown to have only a very modest impact on outcome in recurrent, persistent, or metastatic cervix cancer. Despite this fact, when cisplatin is administered concurrently with external beam radiation as a 'chemosensitizing' strategy, both progression-free and overall survival have been shown in multiple evidence-based randomized trials to be improved compared to the delivery of radiation alone. Ongoing research in this area has focused on improving the drug component of this strategy and on following the concurrent chemoradiation with systemic ('adjuvant') therapy. Copyright © 2013 S. Karger AG, Basel.

Markman M.,Cancer Treatment Centers of America | Markman M.,Drexel University
Cancer and Metastasis Reviews | Year: 2015

The fundamental goal of maintenance therapy of cancer is to extend a clinically meaningful survival endpoint (overall, symptom-free, progression-free) while at the same time not substantially interfering with a patient’s quality of life. Several phase 3 randomized trials in ovarian cancer involving different anti-neoplastics (e.g., paclitaxel, anti-angiogenic agents, olaparib) have revealed an improvement in progression-free survival with generally acceptable side effect profiles, and as a result represent in appropriately selected patients a rational therapeutic strategy. © 2014, Springer Science+Business Media New York.

Markman M.,Cancer Treatment Centers of America
JNCCN Journal of the National Comprehensive Cancer Network | Year: 2011

Unfortunately, no reliable evidence-based data have shown any in vitro chemosensitivity assay strategy to be clinically useful in the management of recurrent ovarian cancer, despite frequent use. Several clinical trials have been proposed with the potential to support or refute the relevance of these approaches. © JNCCN-Journal of the National Comprehensive Cancer Network.

Markman M.,Cancer Treatment Centers of America
Annals of Oncology | Year: 2013

Secondary cytoreduction in the management of patients with recurrent ovarian cancer is a commonly employed strategy. Unfortunately, there remain 'no evidence-based phase III trial data' to demonstrate the survival benefits of this approach compared with the reintroduction of chemotherapy without surgery at the time of documented progression of the cancer. In the absence of such evidence, it is critical that gynecologic oncologists employ their best clinical judgment when deciding if an individual patient is an appropriate candidate for this as yet unproven strategy. © The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Markman M.,Cancer Treatment Centers of America
Cancer Management and Research | Year: 2011

Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. The drug is frequently employed as a single agent in the platinum-resistant setting, and recently reported data reveal the superiority of the combination of PLD plus carboplatin, compared with the platinum drug plus paclitaxel, in elaying the time to disease progression in women with recurrent (potentially platinum-sensitive) disease. Current research efforts involving PLD in ovarian cancer are focusing on adding novel targeted drugs to this cytotoxic agent. The utility of such approaches in the platinum-resistant population, compared with the sequential administration of single agents active in this setting, remains to be determined. © 2011 Markman.

Discover hidden collaborations